## Abstract To evaluate the associations of breast cancer risk with polymorphisms in the __XPC__ and __XPD/ERCC2__ DNA nucleotide excision repair genes, a caseβcontrol study nested within a prospective cohort of 14,274 women was conducted. Genotypes were characterized for 612 incident, invasive bre
Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer
β Scribed by Beth O. Van Emburgh; Jennifer J. Hu; Edward A. Levine; Libyadda J. Mosley; L. Douglas Case; Hui-Yi Lin; Sommer N. Knight; Nancy D. Perrier; Peter Rubin; Gary B. Sherrill; Cindy S. Shaw; Lisa A. Carey; Lynda R. Sawyer; Glenn O. Allen; Clara Milikowski; Mark C. Willingham; Mark Steven Miller
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 146 KB
- Volume
- 47
- Category
- Article
- ISSN
- 0899-1987
- DOI
- 10.1002/mc.20365
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Polymorphisms in phase I and phase II enzymes may enhance the occurrence of mutations at critical tumor suppressor genes, such as p53, and increase breast cancer risk by either increasing the activation or detoxification of carcinogens and/or endogenous estrogens. We analyzed polymorphisms in CYP1B1, GSTM1, GSTT1, and GSTP1 and p53 mutations in 323 breast tumor samples. Approximately 11% of patients exhibited mutations in p53. Women with mutations had a significantly younger age of diagnosis (Pβ=β0.01) and a greater incidence of tumors classified as stage II or higher (Pβ=β0.002). More women with mutations had a history of smoking (55%) compared to women without mutations (39%). Although none of the genotypes alone were associated with p53 mutations, positive smoking history was associated with p53 mutations in women with the GSTM1 null allele [ORβ=β3.54; 95% CIβ=β0.97β12.90 Pβ=β0.06] compared to women with the wildβtype genotype and smoking history [ORβ=β0.62, 95% CIβ=β0.19β2.07], although this association did not reach statistical significance. To test for geneβgene interactions, our exploratory analysis in the Caucasian cases suggested that individuals with the combined GSTP1 105 VV, CYP1B1 432 LV/VV, and GSTM1 positive genotype were more likely to harbor mutations in p53 [ORβ=β4.94; 95% CIβ=β1.11β22.06]. Our results suggest that geneβsmoking and geneβgene interactions may impact the prevalence of p53 mutations in breast tumors. Elucidating the etiology of breast cancer as a consequence of common genetic polymorphisms and the genotoxic effects of smoking will enable us to improve the design of prevention strategies, such as lifestyle modifications, in genetically susceptible subpopulations. Β© 2007 WileyβLiss, Inc.
π SIMILAR VOLUMES
We investigated if the presence of single nucleotide polymorphisms (SNPs) in the XRCC1, XRCC3, and XPD genes were associated with the type and frequency of p53 mutations in bladder cancer. Using a hospital-based case-control study we have previously reported risks for the XRCC1 codon 194, XRCC1 codo
## Abstract p21^WAF1/CIP1^, transcribed from the __CDKN1A__ locus, plays a key role executing p53βinduced growth arrest. The recent discovery that an alternative transcript, p21B, induces apoptosis, suggests an additional important function of this gene. Here, we report __p21__ and __p21B__ mutatio
## Abstract Cigarette smoking has been identified as a risk factor for rectal cancer. Our investigation evaluates associations between active and passive smoking and __TP53__, __KRAS2__, and __BRAF__ V600E mutations, microsatellite instability (MSI), and CpG Island Methylator Phenotype (CIMP) in re